Rainer Haag

Prof. Rainer Haag

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2006 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
RHRainer Haag
Rainer Haag
FKFelix Kratz
Felix Kratz

5 September 2012 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
CFCarlo Fasting
Carlo Fasting
CSChristoph A. Schalley
Christoph A. Schalley
MWMarcus Weber
Marcus Weber
OSOliver Seitz
Oliver Seitz
SHStefan Hecht
Stefan Hecht
RHRainer Haag
Rainer Haag
Multivalent interactions can be applied universally for a targeted strengthening of an interaction between different interfaces or molecules. The binding partners form cooperative, multiple receptor–ligand interactions that are based on individually weak, noncovalent bonds and are thus generally reversible. Hence, multi‐ and polyvalent interactions play a decisive role in biological systems for recognition, adhesion, and signal processes. The scientific and practical realization of this principle will be demonstrated by the development of simple artificial and theoretical models, from natural systems to functional, application‐oriented systems. In a systematic review of scaffold architectures, the underlying effects and control options will be demonstrated, and suggestions will be given for designing effective multivalent binding systems, as well as for polyvalent therapeutics.

15 July 2014 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
QWQiang Wei
Qiang Wei
TBTobias Becherer
Tobias Becherer
SAStefano Angioletti‐Uberti
Stefano Angioletti‐Uberti
JDJoachim Dzubiella
Joachim Dzubiella
CWChristian Wischke
Christian Wischke
RHRainer Haag
Rainer Haag

28 December 2009 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
MCMarcelo Calderon
Marcelo Calderon
MQMohiuddin Abdul Quadir
Mohiuddin Abdul Quadir
SSSunil Kumar Sharma
Sunil Kumar Sharma
RHRainer Haag
Rainer Haag

11 January 2017 in Chemical Reviews
Verified
Journal Article
Closed access
CCChong Cheng
Chong Cheng
Shuang LiShuang Li
Shuang Li
ATArne Thomas
Arne Thomas
NKNicholas A. Kotov
Nicholas A. Kotov
RHRainer Haag
Rainer Haag

12 December 2011 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
JKJayant Khandare
Jayant Khandare
MCMarcelo Calderon
Marcelo Calderon
NDNilesh M. Dagia
Nilesh M. Dagia
RHRainer Haag
Rainer Haag
Nanotechnology has resulted in materials that have greatly improved the effectiveness of drug delivery because of their ability to control matter on the nanoscale. Advanced forms of nanomedicine have been synthesized for better pharmacokinetics to obtain higher efficacy, less systemic toxicity, and better targeting. These criteria have long been the goal in nanomedicine, in particular, for systemic applications in oncological disorders. Now, the “holy grail” in nanomedicine is to design and synthesize new advanced macromolecular nanocarriers and to translate them from lab to clinic. This review describes the current and future perspectives of nanomedicine with particular emphasis on the clinical targets in cancer and inflammation. The advanced forms of liposomes and polyethylene glycol (PEG) based nanocarriers, as well as dendritic polymer conjugates will be discussed with particular attention paid to designs, synthetic strategies, and chemical pathways. In this critical review, we also report on the current status and perspective of dendritic polymer nanoconjugate platforms (e.g. polyamidoamine dendrimers and dendritic polyglycerols) for cellular localization and targeting of specific tissues (192 references).